Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NASD]
Sanofi
Index- P/E32.88 EPS (ttm)1.52 Insider Own16.40% Shs Outstand2.49B Perf Week2.61%
Market Cap124.42B Forward P/E13.65 EPS next Y3.66 Insider Trans0.00% Shs Float2.23B Perf Month1.81%
Income3.82B PEG4.38 EPS next Q- Inst Own8.20% Short Float0.06% Perf Quarter0.02%
Sales42.35B P/S2.94 EPS this Y-32.80% Inst Trans4.20% Short Ratio0.52 Perf Half Y9.66%
Book/sh26.25 P/B1.90 EPS next Y8.28% ROA- Target Price56.25 Perf Year20.30%
Cash/sh- P/C- EPS next 5Y7.50% ROE- 52W Range37.62 - 51.84 Perf YTD-0.50%
Dividend1.70 P/FCF- EPS past 5Y-6.40% ROI3.50% 52W High-3.65% Beta0.58
Dividend %3.40% Quick Ratio- Sales past 5Y3.30% Gross Margin68.00% 52W Low32.78% ATR1.10
Employees100409 Current Ratio- Sales Q/Q6.90% Oper. Margin16.20% RSI (14)63.32 Volatility1.63% 2.00%
OptionableYes Debt/Eq- EPS Q/Q47.40% Profit Margin13.60% Rel Volume0.98 Prev Close49.58
ShortableYes LT Debt/Eq- EarningsApr 24 BMO Payout0.00% Avg Volume2.62M Price49.95
Recom1.40 SMA203.60% SMA506.48% SMA2006.47% Volume2,573,458 Change0.75%
Mar-17-20Upgrade Barclays Underweight → Equal Weight
Mar-11-20Upgrade Goldman Neutral → Buy
Feb-11-20Initiated SVB Leerink Mkt Perform
Jan-06-20Upgrade JP Morgan Neutral → Overweight
Sep-23-19Upgrade Guggenheim Neutral → Buy
Sep-20-19Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19Initiated Bernstein Outperform
Aug-14-19Upgrade UBS Neutral → Buy
Dec-11-18Upgrade Jefferies Hold → Buy
Nov-01-18Upgrade Barclays Underweight → Equal Weight
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Neutral → Buy
Aug-10-18Upgrade Citigroup Neutral → Buy
Mar-23-18Upgrade Liberum Hold → Buy
Jan-23-18Downgrade Barclays Equal Weight → Underweight
Dec-06-17Downgrade BofA/Merrill Buy → Neutral
Dec-01-17Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17Upgrade Barclays Underweight → Equal Weight
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Jun-04-20 03:22PM  
11:31AM  
Jun-03-20 01:13PM  
01:03PM  
05:56AM  
Jun-02-20 04:51PM  
07:45AM  
03:07AM  
Jun-01-20 09:57AM  
07:57AM  
07:50AM  
06:07AM  
May-31-20 05:32PM  
May-29-20 11:00PM  
08:59PM  
05:25PM  
03:36PM  
12:22PM  
09:37AM  
May-28-20 09:45PM  
03:42PM  
11:34AM  
May-27-20 06:13PM  
12:16PM  
10:35AM  
10:08AM  
08:13AM  
07:25AM  
01:28AM  
May-26-20 11:19PM  
01:50PM  
12:06PM  
11:53AM  
10:52AM  
10:41AM  
09:55AM  
09:03AM  
08:44AM  
07:54AM  
06:54AM  
06:48AM  
06:45AM  
May-25-20 10:04PM  
01:20PM  
12:40PM  
03:26AM  
May-24-20 08:21AM  
May-23-20 09:15AM  
May-22-20 10:29PM  
10:31AM  
09:22AM  
07:29AM  
07:00AM  
06:16AM  
04:19AM  
02:51AM  
May-21-20 03:48PM  
12:55PM  
11:45AM  
09:15AM  
May-20-20 12:00PM  
May-19-20 05:52AM  
May-18-20 10:03AM  
May-17-20 04:15PM  
May-15-20 10:45AM  
06:46AM  
03:18AM  
12:00AM  
May-14-20 10:46PM  
06:49PM  
03:44PM  
03:19PM  
02:23PM  
02:01PM  
12:49PM  
11:51AM  
11:50AM  
11:43AM  
11:16AM  
11:16AM  
10:45AM  
10:45AM  
10:32AM  
09:54AM  
09:29AM  
08:47AM  
08:39AM  
08:35AM  
08:28AM  
06:29AM  
06:22AM  
05:42AM  
02:37AM  
May-13-20 11:15PM  
04:51PM  
04:46PM  
04:42PM  
04:12PM  
02:28PM  
10:44AM  
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; and GlaxoSmithKline Plc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerMay 29Sale509.852,399,5521,223,411,587400,000May 29 04:16 PM
Sanofi10% OwnerMay 29Sale509.8520,421,89910,412,105,2050May 29 04:16 PM
Sanofi10% OwnerMar 09Sale489.65128,91463,123,15320,421,899Mar 11 05:00 PM
Sanofi10% OwnerSep 10Sale281.15172,90448,611,80420,550,813Sep 12 05:00 PM
Sanofi10% OwnerJul 22Buy16.0093,7501,500,000558,035Jul 23 11:39 AM